Literature DB >> 20671415

Correlation between genotype and hormonal levels in heterozygous mutation carriers and non-carriers of 21-hydroxylase deficiency.

E Napolitano1, C Manieri, F Restivo, E Composto, F Lanfranco, M Repici, B Pasini, S Einaudi, E Menegatti.   

Abstract

Congenital adrenal hyperplasia, both in its classic (CCAH) and non-classic form (NCAH), is a morbid condition sustained by the absent or reduced function of one of the enzymes involved in cortisol biosynthesis - mainly 21 hydroxylase - associated with different levels of clinical androgenization. In a wide group of relatives of patients affected by CCAH and NCAH (no.=222) and healthy volunteers (no.=30), a clinical, hormonal and genetic evaluation was performed in order to differentiate between the condition of heterozygous mutation carrier and non-carrier of any among 21-hydroxylase gene (CYP21) mutations. This study shows that clinical presentation and basal 17α-hydroxyprogesterone (17α-OHP) are not able to differentiate between heterozygous carriers and non-carriers, whereas 17α-OHP value after ACTH bolus is significantly different between heterozygous carriers and non-carriers: p<0.001 with a cut-off value of 3 ng/ml (90% sensitivity and 74,3% specificity). Moreover, our data indicate that 17α-OHP response to ACTH may be a useful tool to select subjects for genetic analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671415     DOI: 10.3275/7225

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

Review 1.  Clinical impact of molecular diagnostics in endocrinology. Polymorphisms, mutations and DNA technologies.

Authors:  Wolfgang Höppner
Journal:  Horm Res       Date:  2002

Review 2.  Extensive clinical experience: nonclassical 21-hydroxylase deficiency.

Authors:  Maria I New
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

3.  HLA typing and ACTH stimulation in the detection of carriers for 21-hydroxylase deficiency.

Authors:  M S Stuckey; P Boyne; W B Macdonald; F T Christiansen; J B Houliston; R L Dawkins
Journal:  Aust N Z J Med       Date:  1980-10

4.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.

Authors:  N Krone; A Braun; A A Roscher; D Knorr; H P Schwarz
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

5.  The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations.

Authors:  H F Escobar-Morreale; J L San Millán; R R Smith; J Sancho; S F Witchel
Journal:  Fertil Steril       Date:  1999-10       Impact factor: 7.329

6.  Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism?

Authors:  A Vottero; M Capelletti; S Giuliodori; I Viani; M Ziveri; T M Neri; S Bernasconi; L Ghizzoni
Journal:  J Clin Endocrinol Metab       Date:  2006-01-10       Impact factor: 5.958

7.  Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.

Authors:  Osnat Admoni; Shosh Israel; Idit Lavi; Michal Gur; Yardena Tenenbaum-Rakover
Journal:  Clin Endocrinol (Oxf)       Date:  2006-06       Impact factor: 3.478

Review 8.  Prenatal diagnosis and treatment of congenital adrenal hyperplasia.

Authors:  L S Levine; S Pang
Journal:  J Pediatr Endocrinol       Date:  1994 Jul-Sep

Review 9.  Antenatal diagnosis and treatment of congenital adrenal hyperplasia.

Authors:  M I New
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 2.862

10.  Prenatal diagnosis of a heterozygote of salt wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency by genetic linkage analysis.

Authors:  B H Oh; J K Park; Y M Choi; I M Yang; Y S Kim; Y K Choi
Journal:  J Korean Med Sci       Date:  1988-06       Impact factor: 2.153

View more
  3 in total

1.  Genotype in the diagnosis of 21-hydroxylase deficiency: who should undergo CYP21A2 analysis?

Authors:  P Cavarzere; M Vincenzi; F Teofoli; R Gaudino; S Lauriola; E Maines; M Camilot; F Antoniazzi
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

2.  17-Hydroxyprogesterone Response to Standard Dose Synacthen Stimulation Test in CYP21A2 Heterozygous Carriers and Non-carriers in Symptomatic and Asymptomatic Groups: Meta-analyses

Authors:  Seher Polat; Yusuf Kemal Arslan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2021-11-08

3.  POR polymorphisms are associated with 21 hydroxylase deficiency.

Authors:  F Pecori Giraldi; S Einaudi; A Sesta; F Verna; M Messina; C Manieri; E Menegatti; L Ghizzoni
Journal:  J Endocrinol Invest       Date:  2021-03-05       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.